Print   

Thursday 25 June, 2009

Medicsight Plc

Global agreement with Alma IT

RNS Number : 4635U
Medicsight Plc
25 June 2009
 



 

Press Release

25 June 2009


Medicsight PLC


('Medicsight' or 'the Company')


Global agreement with Alma IT Systems

Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, is pleased to announce it has signed a non-exclusive, software license and distribution agreement  with Alma IT Systems ('Alma')a leading developer of advanced digital medical imaging tools,  across Europe and South America. This will give Medicsight access to Alma's large and established installed base of radiology customers in key markets.

As part of this agreement Medicsight's ColonCAD API 4.0 software will be integrated into Alma's latest Colon viewer, a 3D visualisation workstation which interprets computed tomographic colonography (CTC) image data. Alma is one of Spain's market leaders in medical imaging technology. It is anticipated that the new product will be offered to both clinicians and PACS customers via the ALMA 3D workstation and server-based client platforms.

Commenting on the partnership Jacobo Gil de Biedma, co-founder and CEO of Alma IT Systems, said 'Alma is a market leader in medical imaging software in Spain and we are quickly gaining market share in Europe and South America.  We are seeing a growing demand for CT colonography imaging tools By developing the latest Alma Colon viewer with the integration of Medicsight's latest ColonCAD application, we can offer our clients complete, fast and reliable  imaging technology and continue to consolidate the ALMA 3D platform as a one-stop solution'. 

Allan Rowley, Chief Executive of Medicsight commented 'This agreement provides Medicsight with an ideal commercial opportunity to work with Alma and further extend our reach into the European and South American medical imaging markets. We look forward to the swift roll out of the integrated technology'.

The prototype Alma 3D Colon viewer is available for demonstration on the Medicsight booth  (number 13at the 20th Annual European Society of Gastrointestinal and Abdominal Radiology (ESGAR 2009) taking place this week in Valencia. 


- ENDS -


For further information:

Medicsight PLC

www.medicsight.com

Allan Rowley

+44 (0)20 7605 7950

Daniel Stewart & Company PLC

 

Simon Leathers / Charlotte Stranner

+44 (0) 20 7776 6550 

Media enquiries:

Abchurch Communications

+44 (0) 20 7398 7700

Heather Salmond / Stephanie Cuthbert / Simone Alves

+44 (0) 20 7398 7718

stephanie.cuthbert@abchurch-group.com

www.abchurch-group.com



Notes to editors 


About 


Alma IT Systems is comprised of a group of professionals who are dedicated to the design and development of computer programs for the medical field.

Located in BarcelonaAlma is the result of more than eight years of research with the Universitat Politècnica de Catalunya, which is currently backed by the Medical School of Bern.

In collaboration with the leading departments of R&D and design, we work to offer medical professionals advanced tools that allow them to carry out diagnostics for images and pre-surgical planning on their personal computer with complete comfort and flexibility.

Our ultimate goal is to develop products that offer specific tools for each medical specialty so that it may be possible to carry out simultaneous surgeries in real time. 

Alma IT Systems has implemented a Quality Management System according to the ISO 13485 and ISO 9001 international standards certified by SGS United Kingdom Limited. 


Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software  automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD and LungCAD software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.


About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.



About Medicsight's CAD software

Medicsight's ColonCAD and LungCAD software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.


Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.


Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development.  Medicsight also collaborates with a number of leading academic institutions and clinical research  programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest  possible standards.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRUSONRKWRNUAR

Investegate takes no responsibility for the accuracy of the information within the site.


The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.



Investegate      © 2012 FE. All rights reserved.